证券代码：600535 证券简称：天士力 编号：临 2025-001 号 天士力医药集团股份有限公司 关于华润三九收到《经营者集中反垄断审查不予禁止决定书》的公告 2025 年 1 月 27 日，天士力医药集团股份有限公司（以下简称"天士力"、"公 司"）收到华润三九医药股份有限公司（以下简称"华润三九"）发来的通知，华 润三九已于近日收到国家市场监督管理总局出具的《经营者集中反垄断审查不予 禁止决定书》（反执二审查决定[2025]72 号），具体情况如下： 一、基本情况概述 公司于 2024 年 8 月 5 日披露了《天士力关于控股股东及其一致行动人签署< 股份转让协议>暨控制权变更的提示性公告》（公告编号：临 2024-030 号），公司 控股股东天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其一 致行动人天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发展合伙企业 （有限合伙）、天津鸿勋科技发展合伙企业（有限合伙）、天津通明科技发展合伙 企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展 合伙企业（有限合伙）与华润三九签订了《股份转让协议》。根据协议内容，天 士力集团 ...

Core Insights - The article highlights the importance of art education in rural areas, emphasizing its role in enhancing children's confidence and creativity [6][23][38] - The Tianshili Public Welfare Foundation is actively involved in supporting education in remote regions, focusing on improving children's psychological well-being and artistic skills [3][17][31] Group 1: Educational Initiatives - The Tianshili Public Welfare Foundation has been organizing art education programs in rural schools, providing children with opportunities to explore their artistic talents [28][31] - Various specialized teachers are engaged in teaching different subjects, such as music, art, and psychology, to address the children's emotional and educational needs [2][12][36] Group 2: Community Impact - The foundation's efforts are contributing to a significant transformation in rural education, fostering a sense of hope and aspiration among children [8][21][22] - The initiative aims to bridge the educational gap by bringing professional educators to remote areas, thereby enhancing the overall quality of education [9][27][35] Group 3: Long-term Vision - The foundation's commitment to education is part of a broader strategy to promote balanced educational development and improve the quality of life for children in rural communities [17][30][31] - By integrating art into education, the foundation seeks to cultivate a positive mindset and encourage children to pursue their dreams [5][6][23]

Core Viewpoint - Rural revitalization is not merely about providing aid but enhancing self-sustaining capabilities [1] Group 1: Project Design and Implementation - Tianjin Tianshi focuses on innovation and sustainability in project design to stimulate the endogenous power of rural areas [5][43] - The "Jude Town" project is a model for rural industrial revitalization, integrating ecological living, characteristic industries, and rural tourism [44] - The foundation has established a cooperative for planting medicinal herbs and fruits, and raising local livestock, utilizing modern agricultural practices and e-commerce to promote sales [46] Group 2: Role of Social Forces - The foundation plays a crucial role in empowering rural areas and promoting sustainable development through social participation [6][25] - Various social forces, including government, enterprises, and organizations, are collaborating to support educational initiatives and rural revitalization [9][10] - The foundation's efforts in education, such as the "Angel's Love" project, aim to nurture a new generation of responsible and talented individuals [7][8] Group 3: Technological Integration - The use of big data and artificial intelligence allows the foundation to accurately identify beneficiaries and their needs [12][54] - Digital transformation expands channels for public welfare and enhances interaction with the public, increasing transparency and credibility [13][14] - Intelligent management systems improve operational efficiency and reduce labor costs for the foundation [26][27] Group 4: Sustainable Development - The foundation emphasizes green and sustainable development in its projects, aiming for a harmonious living environment for future generations [31][32][58] - The "授人以渔" (teach a man to fish) approach promotes local economic development while preserving ecological and cultural heritage [33][47] - The foundation's initiatives contribute to both economic and social benefits, creating a win-win situation [33][47] Group 5: Community Engagement and Impact - The foundation's activities have fostered a strong sense of community and social cohesion, with volunteers receiving widespread respect and appreciation [40][51] - The foundation's work alleviates short-term pressures on government resource allocation and compensates for market deficiencies in public services [52] - The foundation serves as a bridge connecting social resources with public interests, continuously innovating its welfare models [53]

证券代码：600535 证券简称：天士力 编号：临 2024-055 号 天士力医药集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 被担保人名称：济南平嘉大药房有限公司（以下简称"济南平嘉"）。 本次担保金额及已实际为其提供的担保余额：天士力医药集团股份有限公司 （以下简称"公司"）为济南平嘉提供担保金额500万元人民币。截至目前，已实际 为济南平嘉提供的担保余额为2,751万元人民币。 本次担保是否有反担保：无。 对外担保逾期的累计数量：无。 特别风险提示：本次被担保人济南平嘉的资产负债率超过70%，敬请投资者 注意相关风险。 一、担保情况概述 1、本次担保事项的基本情况 2024年12月27日，公司与中国光大银行股份有限公司济南分行签署了《最高额 保证合同》，为济南平嘉提供最高债权限额500万元人民币的连带责任保证担保。截 至目前，公司已实际为济南平嘉提供的担保余额为2,751万元人民币。上述担保在 2023年年度股东大会审议批准的额度范围内，无需再次 ...

一、药品的基本情况 药品名称：巴氯芬口服溶液 剂型：口服溶液剂 证券代码：600535 证券简称：天士力 编号：临 2024-054 号 天士力医药集团股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）之全资子公司江 苏天士力帝益药业有限公司（以下简称"江苏帝益"）收到国家药品监督管理局 核准签发的关于巴氯芬口服溶液的《药品注册证书》，现将相关情况公告如下： 公司巴氯芬口服溶液申请于 2023 年 4 月 17 日获得 CDE 受理（受理号： CYHS2301070），并于近日获得国家药品监督管理局核准签发的《药品注册证书》。 截至目前，江苏帝益针对该药品的累计研发投入为 1,102.61 万元人民币。 根据产品说明书，巴氯芬口服溶液适应症为适用于多发性硬化症所引起的严 重但可逆的肌肉痉挛，对感染性、退行性、外伤性、肿瘤或原因不明的脊髓疾病 引起的痉挛可能有一定的疗效。巴氯芬口服溶液由诺华研发，最早于 1984 年在 爱尔兰 ...

Investment Rating - The report gives a "Buy" rating for the company, with a target price of 14.53 yuan [5] Core Views - The company's performance in Q3 2024 is under short-term pressure, with revenue of 6.463 billion yuan, down 1.66% YoY, and net profit attributable to the parent company of 842 million yuan, down 18.41% YoY [2] - The cardiovascular business remains stable, with revenue of 4.24 billion yuan, up 3.54% YoY, while the anti-tumor and liver disease treatment businesses grew by 22.68% and 12.64% respectively [2] - The company's core products, such as Compound Danshen Dripping Pills, are expected to stabilize after the impact of centralized procurement policies in 2023 [2] - Huaren Sanniu's potential takeover is seen as a positive development, with expectations of enhanced management, marketing, and policy resources [2] Financial Performance - The company's gross margin, net profit margin, and non-GAAP net profit margin for the first three quarters of 2024 were 66.8%, 13.0%, and 15.2%, respectively, down 0.05, 2.68, and 0.84 percentage points YoY [2] - For Q3 2024, the gross margin, net profit margin, and non-GAAP net profit margin were 65.4%, 8.6%, and 11.8%, down 2.78, 6.32, and 4.8 percentage points YoY [2] - Revenue for 2024-2026 is forecasted to be 8.615 billion yuan, 8.938 billion yuan, and 9.537 billion yuan, with net profit attributable to the parent company of 1.023 billion yuan, 1.176 billion yuan, and 1.363 billion yuan, respectively [3] - The current PE ratios for 2024-2026 are estimated at 21.2X, 18.5X, and 15.9X [3] Business Segments - Cardiovascular business: Revenue of 4.24 billion yuan, up 3.54% YoY [2] - Anti-tumor business: Revenue of 166 million yuan, up 22.68% YoY [2] - Liver disease treatment: Revenue of 532 million yuan, up 12.64% YoY [2] - Cold and fever treatment: Revenue of 239 million yuan, down 36.42% YoY, mainly due to declining sales of Huoxiang Zhengqi Dripping Pills and Chuanxinlian Nei Zhi Dripping Pills [2] Valuation and Forecast - The company's revenue for 2024-2026 is expected to grow at a CAGR of 3.7%, with net profit attributable to the parent company growing at a CAGR of 15.9% [3] - The EPS for 2024-2026 is forecasted to be 0.69 yuan, 0.79 yuan, and 0.91 yuan, respectively [3] - The ROE for 2024-2026 is expected to be 8.0%, 8.8%, and 9.7%, respectively [4] Industry Outlook - The pharmaceutical industry, particularly the cardiovascular and anti-tumor segments, shows strong growth potential, supported by the company's core products and Huaren Sanniu's potential takeover [2][3]

关于控股子公司研发项目暂停临床试验并计提减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）控股子公司天士力生物 医药股份有限公司（以下简称"天士力生物"）之控股子公司上海赛远生物科技 有限公司（以下简称"赛远生物"）研发的重组全人源抗 EGFR 单克隆抗体注射 液（以下简称"安美木单抗"）目前处于 II 期临床试验。根据近期得出的《IIb 期 临床研究报告（期中分析）》结论，公司组织外部专家和内部医药产品创新研发 决策委员会进行技术和市场分析，审慎考量后续研发投入风险和商业化市场前景 等多种不确定性因素，结合公司研发管理策略，为合理配置研发资源、聚焦研发 管线中的优势项目，经公司总经理办公会审议决定暂停安美木单抗的临床试验， 同时为更加客观、准确地反映公司财务状况和资产价值，根据《企业会计准则》 等相关规定，本着谨慎性原则，将该项目开发支出余额全额计提资产减值准备， 现将有关情况公告如下： 注册分类：治疗用生物制品 1 类 一、暂停临床试验药物的基本信息 证券代 ...

证券代码：600535 证券简称：天士力 编号：临 2024-051 号 天士力医药集团股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 二、说明会召开的时间、地点 （一）会议召开时间：2024 年 11 月 27 日下午 16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 1 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 20 日（星期三）至 2024 年 11 月 26 日（星期 二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公 司邮箱 stock@tasly.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 26 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公司 ...

Group 1 - The company held a shareholders' meeting on November 11, 2024, at its headquarters in Tianjin, with all board members present [1] - The meeting adopted a combination of on-site and online voting methods, presided over by the chairman, Yan Kaijing [1] - The attendance included 9 out of 9 current directors and 4 out of 5 current supervisors, with one supervisor absent due to work commitments [1] Group 2 - The proposal for the third quarter profit distribution for 2024 was approved during the meeting [2] - The voting for the proposal was a non-cumulative voting process, requiring a simple majority of the valid votes cast by attending shareholders [2] - The meeting was legally witnessed by lawyers from Inner Mongolia Jianzhong Law Firm, confirming that the meeting's procedures and voting results were valid and compliant with relevant laws and regulations [2]